Norditropin Daily denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare requires prior authorization for Norditropin (daily somatropin) under its Commercial growth hormone policy, and defines an "essential" use of growth hormone as therapy to treat a deficiency as part of chronic disease management, distinguishing it from non-essential replacement uses . Covered indications follow FDA labeling and include Congenital Growth Hormone Deficiency (GHD), Pediatric GHD, Transition Phase Adolescent GHD, Adult GHD, and Prader-Willi Syndrome , with additional pediatric indications such as short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4, and Idiopathic Short Stature (ISS) with height SDS less than -2.25 and growth rates unlikely to permit attainment of adult height in the normal range . Authorization is issued for 12 months at a time , and for transition adolescents the criteria apply during the period from mid to late teens until 6 to 7 years after achievement of adult height . Contraindications per labeling include acute critical illness after open heart or abdominal surgery or multiple accidental trauma, pediatric patients with Prader-Willi syndrome who are severely obese or have upper airway obstruction/sleep apnea, hypersensitivity to somatropin or excipients, and active proliferative or severe non-proliferative diabetic retinopathy . Benefit caps may apply: if the diagnosis is essential the cap is overridden, but if non-essential only the authorization applies and supply limits may be in place . Adult GHD diagnosis typically requires biochemical confirmation (e.g., Insulin Tolerance Test less than 5 ng/mL as the test of choice ) and an endocrinologist must coordinate therapy.

- Submit complete biochemical workup: two failed GH provocative stimulation tests for pediatric GHD per Pediatric Endocrine Society (Grimberg et al., 2016) guidelines, or for adults the Endocrine Society 2011 guideline (Molitch et al.) and AACE/ACE 2019 guideline ( College of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care, Endocr Pract 2019;25(11):1191-1232 ) which support diagnosis with documented pituitary/hypothalamic disease plus low IGF-1 - Provide growth charts demonstrating height SDS and growth velocity, citing Pediatric Endocrine Society guidelines providing recommendations for the clinical management of children and adolescents with growth failure ; if transition-age, cite AACE 2019 transition guidance for retesting - Document open epiphyses by X-ray and ongoing growth velocity >2 cm/year, or document clinical reason for slower response (e.g., late puberty), aligned with Pediatric Endocrine Society recommendations - Confirm prescription is written or co-managed by a board-certified endocrinologist with attestation letter - Demonstrate that contraindications do not apply (e.g., negative sleep study and BMI documentation for PWS patients, ophthalmologic clearance for diabetics, no active neoplasm) per Norditropin prescribing information - Argue essential-use designation: GHD as replacement for a chronic pituitary disease meets UHC's own definition of "therapy to treat a deficiency as part of chronic disease management" , which should override benefit caps - For adult continuation, submit IGF-1 normalization, improvement in body composition, lipid profile, and quality-of-life scores (AGHDA) supporting clinical benefit per Endocrine Society guideline ( Molitch ME et al., Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab )

## Why UnitedHealthcare Flags Norditropin Daily as "Experimental/Investigational"

An "experimental" denial on Norditropin under UnitedHealthcare Commercial is almost never a true investigational determination — somatropin is FDA-approved with decades of labeling. What UHC is actually saying is that the requested indication falls outside its Medical Benefit Drug Policy for Human Growth Hormone – Somatropin (Genotropin, Humatrope, Norditropin, Nutropin AQ, Omnitrope, Saizen, Zomacton), and is therefore being treated as off-label/unproven. The most common triggers: ISS without documented height SDS <-2.25, SGA without confirmed lack of catch-up growth by age 2–4, Adult GHD without an Insulin Tolerance Test (ITT) showing peak GH <5 ng/mL, or a transition-phase adolescent request beyond the 6-to-7-year post-adult-height window.

## The Correct Procedural Channel

Norditropin is adjudicated through OptumRx specialty (BriovaRx/Optum Specialty Pharmacy) under the medical benefit drug policy, not the standard PBM formulary lane. Appeals must route through the UHC Provider Portal → Prior Authorization & Notification → Pharmacy/Specialty Medical Appeal, not the retail pharmacy appeal queue. Filing through the wrong channel is the single most common reason these appeals time out without substantive review. Reference the exact policy by name and version date on the cover letter — UHC reviewers reject appeals that cite a superseded MBDP revision.

## Federal Leverage

Under 29 CFR §2560.503-1(g), ERISA requires UHC to disclose the specific clinical rationale, the policy provision relied on, and any internal rule or guideline applied. A boilerplate "experimental" letter that fails to identify the specific MBDP criterion not met is an ERISA disclosure violation and can be challenged. Pinto v. Aetna Life Ins. Co. (10th Cir. 2014) establishes that the insurer — not the patient — bears the burden of substantiating an experimental classification when the FDA label and peer-reviewed endocrine literature support the use. For pediatric ISS and SGA indications, the Pediatric Endocrine Society and GH Research Society consensus statements are directly on point and rebut an unproven label.

## Building the Rebuttal Record

Submit: (1) ITT or glucagon stimulation results with peak GH numerics for Adult GHD; (2) growth charts demonstrating height SDS, height velocity, and bone age for pediatric requests; (3) endocrinologist attestation (UHC requires endocrine coordination, not PCP-only); (4) MRI ruling out structural pituitary pathology where relevant; (5) IGF-1 SDS. For Prader-Willi denials, include polysomnography confirming the absence of severe sleep apnea — UHC's labeling-based contraindication is the silent driver of many "experimental" denials in this population.

## Tactical Tip

If the internal appeal is upheld, immediately request external IRO review under the ACA — experimental denials are categorically eligible regardless of dollar threshold per 45 CFR §147.136(d). Concurrently file a complaint with the state DOI citing the specific MBDP language and the missing ERISA §503-1(g) disclosure; parallel pressure shortens the IRO turnaround from 45 days to often under 20.